Cell Line Development and Fermentation Sciences
Purification Sciences and Process Support
Analytical Sciences
Formulation Development
Driving biosimilar development from Gene to GMP
Biosimilar Research and Development Capabilities
Developing high quality biosimilars requires a strong research and development footprint and expert scientific resources.
The Biologics Research and Development Centre at CuraTeQ is a fully equipped world class facility spanning 40,000 sq. ft. The facility has dedicated laboratories to support all biosimilar development activities encompassing:
- Cell line development and fermentation sciences
- Process development
- Process characterisation
- Analytical product characterisation
- Formulation development
- Cell based functional assays development
- Clinical immunology
- Scale down model development and up-scaling
Key features of our biosimilar research and development capabilities
Staffed with 100+ highly qualified scientists experienced in novel biologics and biosimilars development
PhD to Masters ratio at 1:3
Extensive product characterisation experience using cutting edge analytical and bioanalytical tools
Good handle of process science and molecular tuning approaches ensuring process consistency and scalability
Strong regulatory focus
A strong network of regulatory and clinical sciences consultants
Integrated and centralised Laboratory Information Management System (LIMS)
Dedicated warehouse, cold rooms, and stability chambers
Cell Line Development and Fermentation Sciences
Purification Sciences and Process Support
Analytical Sciences
Formulation Development
Since its inception, the Biologics Research and Development Centre at CuraTeQ has been instrumental in developing a robust and strategic pipeline of over 14 biosimilar products.
Latest News
10 April 25
CuraTeQ Biologics successfully completes Phase I study for Denosumab biosimilar
Read More
31 January 25
CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar
Read More
21 December 24
CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)
Read More13 December 24
CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar
Read More
12 November 24
EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad
Read More
15 March 24
CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Read More
17 February 24
Auro Peptides completes US FDA inspection with zero observations
Read More17 January 24
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Read More
20 November 23